The enigma of dark matter, the invisible substance that constitutes approximately 85% of the matter in the universe, has long…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
The Unapproved QUAD Cocktail: A Closer Look at its Composition QUAD is a compounded sublingual dose product marketed by MEDVi…
Read More
A New Two-Component Dark Matter Model Explains the Galactic Center Gamma-Ray Excess While Reconciling the Absence of Signals in Dwarf Galaxies
The search for dark matter, the invisible substance believed to constitute approximately 85% of the matter in the universe, has…
Read More
The Invisible Conflict Two-Component Dark Matter Model Explains Discrepancy Between Milky Way Gamma-Ray Excess and Dwarf Galaxy Observations
The pursuit of dark matter, the elusive substance believed to constitute approximately 85 percent of the universe’s total matter, has…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
In the wake of The New York Times’ April 2 profile, which painted MEDVi CEO Matthew Gallagher as a "vibe-coded…
Read More
The Galactic Center Excess and the Mystery of Two-Component Dark Matter: New Research Explains the Silence of Dwarf Galaxies
The pursuit of dark matter remains one of the most profound challenges in modern astrophysics, as this invisible substance is…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
QUAD is marketed by MEDVi as a sublingual, four-drug cocktail for erectile dysfunction, combining three well-known PDE5 inhibitors—sildenafil, tadalafil, and…
Read More
Two-Component Dark Matter Models and the Galactic Center Gamma-Ray Excess: Reconciling the Silence of Dwarf Galaxies
The pursuit of dark matter remains one of the most formidable challenges in modern astrophysics, as this elusive substance constitutes…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
The digital health company MEDVi, recently spotlighted in an April 2 New York Times profile that depicted CEO Matthew Gallagher…
Read More
